127 related articles for article (PubMed ID: 9467486)
1. Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study.
Oxley JD; Abbott CD; Gillatt DA; MacIver AG
Br J Urol; 1998 Jan; 81(1):109-15. PubMed ID: 9467486
[TBL] [Abstract][Full Text] [Related]
2. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases.
Epstein JI; Woodruff JM
Cancer; 1986 Jan; 57(1):111-9. PubMed ID: 2416422
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
4. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
5. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
6. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas.
Soini Y; Pääkkö P; Nuorva K; Kamel D; Lane DP; Vähäkangas K
Virchows Arch A Pathol Anat Histopathol; 1992; 421(3):223-8. PubMed ID: 1413488
[TBL] [Abstract][Full Text] [Related]
8. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
9. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
11. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia.
Humphrey PA; Swanson PE
Pathol Res Pract; 1995 Sep; 191(9):881-7. PubMed ID: 8606869
[TBL] [Abstract][Full Text] [Related]
13. Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors.
Hernes EH; Linja M; Fosså SD; Visakorpi T; Berner A; Winderen M; Koivisto PA
BJU Int; 2000 Aug; 86(3):240-7. PubMed ID: 10930923
[TBL] [Abstract][Full Text] [Related]
14. Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma.
Szende B; Romics I; Minik K; Szabó J; Torda I; Lovász S; Szomor L; Tóth L; Bély M; Kerényi T; Bartók K; Végh A
Prostate; 2001 Oct; 49(2):93-100. PubMed ID: 11582587
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53 protein in prostate cancers of different histologic types.
Losi L; Di Gregorio C; Brausi M; Fante R; Hurlimann J
Pathol Res Pract; 1994 Apr; 190(4):384-8. PubMed ID: 8078807
[TBL] [Abstract][Full Text] [Related]
16. Prostatic adenocarcinoma with urothelial (transitional cell) carcinoma features.
Mai KT; Collins JP; Veinot JP
Appl Immunohistochem Mol Morphol; 2002 Sep; 10(3):231-6. PubMed ID: 12373149
[TBL] [Abstract][Full Text] [Related]
17. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index.
Wright C; Thomas D; Mellon K; Neal DE; Horne CH
Br J Urol; 1995 Feb; 75(2):173-9. PubMed ID: 7850321
[TBL] [Abstract][Full Text] [Related]
18. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
19. [The role of repeated biopsies in prognosis of prostate cancer].
Romics I; Lovász S; Szabó J; Szomor L; Minik K; Bartók K; Kerényi T; Szende B
Orv Hetil; 2002 Jul; 143(27):1619-23. PubMed ID: 12179998
[TBL] [Abstract][Full Text] [Related]
20. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
